Fernandes Maria Gabriela O, Cruz-Martins Natália, Machado José Carlos, Costa José Luís, Hespanhol Venceslau
Pulmonology Department, Centro Hospitalar Universitário de São João, Alameda Prof. Hernâni Monteiro, 4200-319, Porto, Portugal.
Faculty of Medicine, University of Porto, Alameda Prof. Hernani Monteiro, 4200-319, Porto, Portugal.
Cancer Cell Int. 2021 Dec 16;21(1):675. doi: 10.1186/s12935-021-02382-0.
Liquid biopsy (LB) has boosted a remarkable change in the management of cancer patients by contributing to tumour genomic profiling. Plasma circulating cell-free tumour DNA (ctDNA) is the most widely searched tumour-related element for clinical application. Specifically, for patients with lung cancer, LB has revealed valuable to detect the diversity of targetable genomic alterations and to detect and monitor the emergence of resistance mechanisms. Furthermore, its non-invasive nature helps to overcome the difficulty in obtaining tissue samples, offering a comprehensive view about tumour diversity. However, the use of the LB to support diagnostic and therapeutic decisions still needs further clarification. In this sense, this review aims to provide a critical view of the clinical importance of plasma ctDNA analysis, the most widely applied LB, and its limitations while anticipating concepts that will intersect the present and future of LB in non-small cell lung cancer patients.
液体活检（LB）通过助力肿瘤基因组分析，推动了癌症患者管理方面的显著变革。血浆循环游离肿瘤DNA（ctDNA）是临床应用中研究最为广泛的肿瘤相关元素。具体而言，对于肺癌患者，液体活检在检测可靶向基因组改变的多样性以及检测和监测耐药机制的出现方面已显示出其价值。此外，其非侵入性有助于克服获取组织样本的困难，提供关于肿瘤多样性的全面视图。然而，使用液体活检来支持诊断和治疗决策仍需进一步阐明。从这个意义上讲，本综述旨在对血浆ctDNA分析（应用最广泛的液体活检）的临床重要性及其局限性提供批判性观点，同时展望将与非小细胞肺癌患者液体活检的现状和未来相交的概念。
